| Nov 14 |
Immuneering GAAP EPS of -$0.49
|
| Nov 13 |
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
|
| Oct 16 |
IMRX Stock Up on FDA's Orphan Drug Tag for Pancreatic Cancer Drug
|
| Oct 15 |
Immuneering rises on orphan drug designation for treatment of pancreatic cancer
|
| Oct 15 |
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
|
| Oct 14 |
Here's Why We're A Bit Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Situation
|
| Oct 2 |
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In September 2024 – Where Do Tesla, Nvidia, Apple, DJT Stock Rank?
|
| Sep 16 |
IMRX Stock Soars on Upbeat Efficacy Data From Pancreatic Cancer Study
|
| Sep 13 |
Why Is Nanocap Immuneering Stock Trading Higher On Friday?
|
| Sep 12 |
Immuneering stock rockets 45% on pancreatic therapy data
|
